3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
11
Cyclophosphamide
8
Gemcitabine
7
Cisplatin
7
tislelizumab
5
Docetaxel
5
Nivolumab
4
Injections
4
spartalizumab
3
regorafenib
3
Trastuzumab
3
Oncolytic Virotherapy
3
Irinotecan
3
Filgrastim
3
Drug Therapy
3
Doxorubicin
3
Carboplatin
3
Bortezomib
3
tazemetostat
2
pazopanib
2
liposomal doxorubicin
2
ganitumab
2
conatumumab
2
belinostat
2
Temozolomide
2
Taxes
2
Tamoxifen
2
Sorafenib
2
Riluzole
2
Radiotherapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
tinostamustine
×
Thoracic
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts